Reports of Biochemistry
and Molecular Biology
Sun, May 5, 2024
[Archive]
Volume 9, Issue 1 (Vol.9 No.1 Apr 2020)
rbmb.net 2020, 9(1): 40-49 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahimi M, Behjati F, Khorram Khorshid H R, Karimlou M, Keyhani E. The Relationship between KIT Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer. rbmb.net 2020; 9 (1) :40-49
URL: http://rbmb.net/article-1-434-en.html
URL: http://rbmb.net/article-1-434-en.html
Maryam Rahimi 
, Farkhondeh Behjati , Hamid Reza Khorram Khorshid , Masoud Karimlou , Elahe Keyhani *
, Farkhondeh Behjati , Hamid Reza Khorram Khorshid , Masoud Karimlou , Elahe Keyhani *
Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. & Clinical Research Development Center of Rofeideh Rehabilitation Hospital, Tehran, Iran.
Abstract: (3373 Views)
Background: KIT is a protooncogene that encodes for the KIT oncoprotein, which is a transmembrane tyrosine kinase growth factor receptor that holds a critical role in a variety of normal physiological and pathological processes including angiogenesis. KIT has been shown to be involved in tumorigenesis, contributing to the development of gastrointestinal carcinoma and leukemia. A link between KIT overexpression and breast cancer development has previously been reported. In the current study, we explored KIT gene expression and exonic copy number variants (CNV) and the relationship with angiogenesis (CD34) and the clinicopathological features of breast cancer.
Methods: MLPA technique was used to determine the CNV in 64 breast cancer tumor samples from patients diagnosed with primary sporadic breast cancer. Results were confirmed by quantitative PCR. Expression of KIT and CD34 was determined using immunohistochemistry (IHC).
Results: Our results show that 28.1% of the tumor samples from patients with primary sporadic breast cancer had CNV in the KIT gene. Among the breast tumor samples, 54.7% showed positive KIT expression. The expression of the CD34 angiogenesis marker was reported in 43.8% of the tumor samples as low, 42.2% as moderate and 14.1% as high. A significant correlation between increased CNV of KIT exons, a high level of angiogenesis (CD34) and increased tumor grade was observed (p< 0.05).
Conclusions: A significant correlation between the KIT CNV and the angiogenesis marker was found. Examining KIT expression and CNV has the potential to function as a biomarker for tyrosine kinase inhibitor drugs in breast cancer.
Methods: MLPA technique was used to determine the CNV in 64 breast cancer tumor samples from patients diagnosed with primary sporadic breast cancer. Results were confirmed by quantitative PCR. Expression of KIT and CD34 was determined using immunohistochemistry (IHC).
Results: Our results show that 28.1% of the tumor samples from patients with primary sporadic breast cancer had CNV in the KIT gene. Among the breast tumor samples, 54.7% showed positive KIT expression. The expression of the CD34 angiogenesis marker was reported in 43.8% of the tumor samples as low, 42.2% as moderate and 14.1% as high. A significant correlation between increased CNV of KIT exons, a high level of angiogenesis (CD34) and increased tumor grade was observed (p< 0.05).
Conclusions: A significant correlation between the KIT CNV and the angiogenesis marker was found. Examining KIT expression and CNV has the potential to function as a biomarker for tyrosine kinase inhibitor drugs in breast cancer.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2019/12/16 | Accepted: 2019/12/25 | Published: 2020/05/19
Received: 2019/12/16 | Accepted: 2019/12/25 | Published: 2020/05/19
References
1. 1. Druillennec S, Dorard C, Eychene A. Alternative Splicing in Oncogenic Kinases: From Physiological Functions to Cancer. J Nucleic Acids. 2012;2012:639062. [DOI:10.1155/2012/639062]
2. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13:383-91. [DOI:10.1111/j.1524-4741.2007.00446.x]
3. Keyhani E, Muhammadnejad A, Behjati F, Sirati F, Khodadadi F, Karimlou M, et al. Angiogenesis Markers in Breast Cancer - Potentially Useful Tools for Priority Setting of Anti-Angiogenic Agents. Asian Pac J Cancer Prev. 2013;14:7651-6. [DOI:10.7314/APJCP.2013.14.12.7651]
4. Shimizu K, Oku N. Cancer anti-antiogenic therapy. Biol Pharm Bull. 2004; 27:599-605. [DOI:10.1248/bpb.27.599]
5. De Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology. 2000;36:306-312. [DOI:10.1046/j.1365-2559.2000.00850.x]
6. Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M, Chatzipantelis P. Expression of c-kit in common benign and malignant breast lesions. Tumori. 2010;96:978-84. [DOI:10.1177/548.6519]
7. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 2005;65(18): 8085-9. [DOI:10.1158/0008-5472.CAN-05-0471]
8. Crosby H A, Kelly D A, Strain J A. Human hepatic stem-like cells isolated using c-kit or CD34 can differentiate into biliary epithelium. Gastroenterology. 2001;120(2):534-44. [DOI:10.1053/gast.2001.21175]
9. Miettinen M, Lasota J. KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205-20. [DOI:10.1097/01.pai.0000173054.83414.22]
10. Tuveson D, Willis N, Jacks T, Gri J, Singer S. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20(36):5054-8. [DOI:10.1038/sj.onc.1204704]
11. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, et al. Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors. Anal Quant Cytol Histol. 2010;32(4):225-33.
12. Antonescu C, Romeo S, Zhang L, Nafa K, Hornick J, Nielsen G, et al. Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT Negative Phenotype: A Diagnostic Pitfall. Morphologic and Molecular Characterization of 8 Cases Occurring either de-novo or after Imatinib Therapy.Am J Surg Pathol. 2013;37(3):385-92. [DOI:10.1097/PAS.0b013e31826c1761]
13. Malaise M, D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep. 2009;4(2):77-82. [DOI:10.1007/s11899-009-0011-8]
14. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22(5):915-31. [DOI:10.1038/leu.2008.19]
15. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821-8. [DOI:10.1158/1078-0432.CCR-08-0575]
16. Lee JY, Park K, Lim S H, Kim H S, Yoo K H, Jung K S, et al. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget. 2015;6(41):43731-42. [DOI:10.18632/oncotarget.6192]
17. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF. Molecular analysis of metaplastic breast carcinoma. Mol Cancer Ther. 2008;7(4):944-51. [DOI:10.1158/1535-7163.MCT-07-0570]
18. Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M, Chatzipantelis P. Expression of c-kit in common benign and malignant breast lesions. Tumori. 2010;96(6):978-84 [DOI:10.1177/548.6519]
19. Johansson I, Aaltonen EK, Ebbesson A, Grabau D, Wigerup C, Hedenfalk I. Increased Gene Copy Number of KIT and VEGFR2 at 4q12 in Primary Breast Cancer is Related to an Aggressive Phenotype and Impaired Prognosis. Genes Chromosomes Cancer. 2012;51(4):375-83 [DOI:10.1002/gcc.21922]
20. Jansson S, Bendah P, Grabau D, Falck A, Aaltonen K. The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRa, Closely Spaced at
21. 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer. PLoS One. 2014;9(7):e102176. [DOI:10.1371/journal.pone.0102176]
22. Zhu Y, Wang Y, Guan B, Rao Q, Wang J, Ma H, et al. C-kit and PDGFRA gene mutations in triple negative breast cancer. Int J Clin Exp Pathol. 2014;7(7):4280-5.
23. Liu J, Liu X, Feng X, Liu J, Lv S, Zhang W, et al. C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast. Breast Cancer Res Treat. 2015;149(2):395-401. [DOI:10.1007/s10549-014-3214-1]
24. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of angiogenic switch concept. Leukemia. 2007;21(1):44-52. [DOI:10.1038/sj.leu.2404402]
25. Rahimi M, Behjati F, Taheri N, Hosseini S, Khorram Khorshid HR, Aghakhani Moghaddam F, et al. Correlation between Important Genes of mTOR Pathway (PI3K and KIT) in Iranian Women with Sporadic Breast Cancer. Med J Islam Repub Iran. 2018;32:135. [DOI:10.14196/mjiri.32.135]
26. Canene-Adams K. Preparation of formalin-fixed paraffin-embedded tissue for immunohistochemistry. Methods Enzymol. 2013;533:225-33. [DOI:10.1016/B978-0-12-420067-8.00015-5]
27. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J ClinOncol. 2002;20:1692-703. [DOI:10.1200/JCO.2002.20.6.1692]
28. Dybko J, Haus O, Jazwiec B, Urbaniak J, Wozniak M, Kaczmar-Dybko A, et al. CD117 (c-kit) expression on CD34? Cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase. Acta Haematol. 2014;132:166-71. [DOI:10.1159/000357373]
29. Carvalho S, Silva A, Milanezi F, Ricardo S, Leita D, Amendoeira I, et al. c-KIT and PDGFRA in breast phyllodes tumours: Over expression without mutations?. J Clin Pathol. 2004;57(10):1075-1079. [DOI:10.1136/jcp.2004.016378]
30. Simon R, Panussis S, Maurer R, Spichtin H, Glatz K, Tapia C, et al. KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT gene Mutations. Clin Cancer Res. 2004;10(1 Pt 1):178-83. [DOI:10.1158/1078-0432.CCR-0597-3]
31. Bose P, Dunn ST, Yang J, Allen R, EL-Khoury C, Tfayli A. c-Kit Expression and Mutations in Phyllodes Tumors of the Breast. Anticancer Res. 2010;30(11):4731-6.
32. Miettinen M, Lasota J. KIT (CD117): a re¬view on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205-20. [DOI:10.1097/01.pai.0000173054.83414.22]
33. Arvas M, Pakula T, Smit B, Rautio J, Koivistoinen H. Correlation of gene expression and protein production rate - a system wide study. BMC Genomics. 2011;12(1):616. [DOI:10.1186/1471-2164-12-616]
34. Chen CM, Chen CJ, Chang CL, Shyu JS, Hsieh HF, Harn HJ. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res. 2000;94(2):84-91. [DOI:10.1006/jsre.2000.6001]
35. Poveda A, del Muro XG, Lopez‑Guerrero JA, Martinez V, Romero I, Valverde C, et al. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol. 2014;74(5):883-98. [DOI:10.1007/s00280-014-2547-0]
36. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20(6):1692-703. [DOI:10.1200/JCO.2002.20.6.1692]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
